CommercialCoverageMedium impact
08.01.48c, Tildrakizumab-asmn (Ilumya®)
Independence Blue Cross·Dermatology·Pharmacy
Effective date
Sep 14, 2026
We identified it
Sep 15, 2026
Summary
Policy 08.01.48c regarding Tildrakizumab-asmn (Ilumya®) has been updated, effective September 14, 2026. The policy change encompasses coverage and/or reimbursement position, medical necessity criteria, medical coding, and general guidelines for this biologic immunosuppressant medication used in dermatology. However, the specific details of what changed cannot be determined from the provided policy metadata alone.
Action Required
By September 14, 2026: Billing team must review the full policy text at the provided URL (https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=09&FilterField2=MPSiteActivityLogYear&FilterValue2=2026#commercial-08-01-48c) to identify specific billing code changes, prior authorization requirements, and medical necessity documentation requirements for Ilumya® claims. Update billing system rules, prior authorization workflows, and provider education materials accordingly. Ensure all claims submitted on or after the effective date comply with new requirements to avoid denials.